Efficacy of Immune Checkpoint Inhibitor on Non-Small Cell Lung Cancer with Chronic Obstructive Pulmonary Disease

<bold>Rationale:</bold> Previous studies have shown that the onset of non–small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) both involve aberrant immune functioning. In this retrospective study, we described the impact of COPD on immune checkpoint inhibitors（ICIs） in NSCLC patients. <bold>Methods:</bold> Patients enrolled in our study were all hospitalized with NSCLC in the West China Hospital from January 1, 2019 to May 1, 2019. They received at least one administration of ICIs at first-line, second-line or third-line. COPD patients were diagnosed by documented spirometry.. We collected progression-free survival (PFS) data. We used the Kaplan-Meier method with log-rank test and Cox proportional hazards to explore the impact. <bold>Results:</bold> 88 NSCLC patients were enrolled in our study and 36 were diagnosed as NSCLC with COPD. We found that NSCLC patients with COPD had a longer PFS (315 vs. 144 days, p=0.016). Furthermore, our results indicate that COPD was not a risk factor for poorer ICIs efficacy in NSCLC patients [hazard ratio (HR) : 0.559, 95% confidence interval (CI): 0.348–0.904, P=0.02]. <bold>Conclusions:</bold> COPD served as a positive factor in the immunotherapy of advanced-stage NSCLC ,which suggested that NSCLC patients with COPD may have more treatment options and the development of novel novel therapies was warranted. <fig><object-id>erj;64/suppl_68/PA4205/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>